C
TG Therapeutics, Inc. TGTX
$41.21 -$0.12-0.29% NASDAQ
Recommendation
Prev Close
$41.33
Volume
915,532
Avg Vol (90D)
2,613,008
Market Cap
$6.56B
Dividend & Yield
--
52-Week Range
$12.93 - $43.32
P/E (TTM)
302.56
EPS (TTM)
$0.1366
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
4/28/2025 - Zacks Investment Research
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Tower Research Capital LLC TRC
4/28/2025 - MarketBeat
Artia Global Partners LP Invests $1.64 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)
4/27/2025 - Ticker Report
Commerce Bank Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
4/27/2025 - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Tower Research Capital LLC TRC
4/26/2025 - Ticker Report
TG Therapeutics (TGTX, $41.33) price may drop as it broke higher Bollinger Band on Apr 25, 2025
4/26/2025 - Tickeron - Stocks
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts
4/26/2025 - MarketBeat
Hood River Capital Management LLC Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
4/25/2025 - MarketBeat
TG Therapeutics Reaches Analyst Target Price
4/25/2025 - ETF Channel
TG Therapeutics (TGTX, $40.3) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 24, 2025
4/25/2025 - Tickeron - Stocks
TG Therapeutics (TGTX, $37.99) entered Uptrend as Momentum indicator ascends above 0 level on Apr 22, 2025
4/23/2025 - Tickeron - Stocks
XTX Topco Ltd Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
4/23/2025 - Ticker Report
481,989 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Raymond James Financial Inc.
4/23/2025 - MarketBeat
TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough
4/23/2025 - SeekingAlpha.com: Most Popular Articles
TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough
4/23/2025 - SeekingAlpha
Guggenheim Capital LLC Lowers Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)
4/22/2025 - Ticker Report
Altium Capital Management LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)
4/20/2025 - MarketBeat
Legal & General Group Plc Sells 7,065 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
4/19/2025 - MarketBeat
TG Therapeutics (TGTX, $38.21) entered Downtrend as Momentum indicator drops below 0 level on Apr 16, 2025
4/17/2025 - Tickeron - Stocks
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Ascendis Pharma (ASND) and McKesson (MCK)
4/17/2025 - TipRanks Financial Blog
Bank of America Securities Reaffirms Their Sell Rating on TG Therapeutics (TGTX)
4/17/2025 - TipRanks Financial Blog
Stocks Sink After Nvidia Warning: TG Therapeutics, Abbott Labs, Loar In Focus
4/16/2025 - Investor's Business Daily
TG Therapeutics: Progress In MS Tempered By High Expectations
4/16/2025 - SeekingAlpha
TG Therapeutics (TGTX, $39.03) entered Uptrend as Momentum indicator ascends above 0 level on Apr 15, 2025
4/16/2025 - Tickeron - Technical Analysis
Price Over Earnings Overview: TG Therapeutics
4/14/2025 - Benzinga
Income Statement
Total Revenue (TTM)
$329.00M
EBITDA (TTM)
$42.00M
EBIT (TTM)
$41.93M
Net Income (TTM)
$23.38M
Balance Sheet
Total Assets (Q)
$577.69M
Total Debt (Q)
$254.38M
Total Liabilities (Q)
$355.33M
Book Value Per Share (Q)
$1.54
Cash Flow
Cash from Operations (TTM)
-$40.52M
Cash from Investing (TTM)
-$1.04M
Cash from Financing (TTM)
$128.53M
Net Change in Cash (TTM)
$86.97M
Filings
Filing Date
Monday, March 3, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.72
7-Day Total Return
7.93%
30-Day Total Return
0.98%
60-Day Total Return
23.62%
90-Day Total Return
28.79%
Year to Date Total Return
32.78%
1-Year Total Return
206.16%
2-Year Total Return
86.61%
3-Year Total Return
511.87%
5-Year Total Return
224.98%
52-week Low
Apr 30, 2024 - $12.93
52-week High
Mar 24, 2025 - $43.32
Valuation
Market Cap
$6.56B - Mid Cap
Enterprise Value
$6.51B
Price/Sales (TTM)
20.13
Price/Book (Q)
26.76
Dividends and Shares
Shares Outstanding
160.24M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tgtherapeutics.com
Phone Number
212 554 4484
Address
3020 Carrington Mill Blvd.
Morrisville, NC 27560
Country
United States
Year Founded
1993
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United... more
NASDAQ 04/28/2025 1:28PM Eastern Quotes delayed